Reflex sympathetic dystrophy (RSD), also known as complex regional pain syndrome type I (CRPS I), is a disabling neuropathic pain syndrome. Controversy exists about the effectiveness of therapeutic interventions for the management of RSD/CRPS I. In order to ascertain appropriate therapies we conducted a review of existing randomized controlled trials of therapies for this disabling disease. Eligible trials were identified from the Cochrane, Pubmed, Embase and MEDLINE databases from 1966 through June 2000, from references in retrieved reports and from references in review articles. Twenty-six studies concerning treatment modalities were identified. Eighteen studies were randomized placebo-controlled trials and eight studies were randomized active-controlled trials. Three independent investigators reviewed articles for inclusion criteria using a 15-item checklist. Seventeen of the trials were of high quality according to the 15-item criteria. There was limited evidence for the effectiveness of these interventions because of the heterogeneity of treatment modalities. The search for trials concerning prevention of RSD/CRPS I resulted in two eligible studies. Both were of high quality and dealt with different interventions. There is limited evidence for their preventive effect. # 2002 European Federation of Chapters of the International Association for the Study of Pain
INTRODUCTION
Complex regional pain syndrome (CRPS) types I and II are neuropathic pain syndromes accompanied by sudomotor and vasomotor disturbances. CRPS I, which corresponds to the common image of reflex sympathetic dystrophy (RSD) is defined as a painful, disabling syndrome (Merskey and Bogduck, 1994) . The Consensus Conference of the International Association for Study of Pain defined CRPS I as a post-traumatic syndrome that presents with spontaneous pain that is not related to the territory of a single nerve and is disproportionate to the inciting event (Merskey and Bogduck, 1994; Schurmann et al., 1999) . The diagnostic criteria include (a) pain, allodynia, or hyperalgesia, (b) evidence at some time of oedema, vasomotor and sudomotor change in the pain region and (c) no other conditions that would otherwise account for the degree of pain and dysfunction. CRPS II is a pain syndrome that starts after a nerve injury and is not necessarily limited to the distribution of the injured nerve (Baron, 2000; Woolf and Mannion, 1999) . The diagnostic criteria are the same as those of CRPS I. CRPS is differentiated from other neuropathic pain syndromes by the existence of oedema, vasomotor and sudomotor disturbances. Some authors previously used a positive response on sympathetic blockade and diffuse or patchy osteopenia as an important diagnostic criterion for RSD (Davidoff et al., 1989; Kozin et al., 1981; Schwartzman and McLellan, 1987) . In CRPS I the role of sympathetic block in diagnosis has been minimized. Consequently, each category under the term CRPS could be divided into patients responsive and unresponsive to sympathetic blocks (Stanton-Hicks et al., 1995) .
Currently practised treatments of RSD/CRPS I include radical scavengers , regional intravenous sympathetic blocks and neuromodulation . Kingery et al. (Kingery, 1997) reviewed existing trials for RSD/CRPS management in 1997 and demonstrated that there is limited support for the effectiveness of topical dimethylsulphoxide (DMSO), epidural clonidine, intravenous regional blocks and intranasal calcitonine. Jadad et al. (1995) showed that there is no evidence for the efficacy of regional intravenous sympathetic (RIS) blockade. We conducted a systematic review of published trials for the treatment and prevention of this disease with an emphasis on randomized controlled trials (RCTs).
MATERIAL AND METHODS

Selection of studies
A computer-assisted search of the Cochrane, Pubmed, Embase and MEDLINE databases from 1966 through June 2000 was conducted using the keywords`complex regional pain syndrome type I',`reflex sympathetic dystrophy' in combination with`trial' or`randomized trials' or random allocation' or`prospective studies' or double/single blind' and`prevention'. Additional reports were identified from reference lists in retrieved reports and in review articles. In 1994 the term CRPS was introduced (Merskey and Bogduck, 1994; Schurmann et al., 1999) . Because of the differences in diagnostic criteria between RSD and currently used CRPS I, studies about RSD and CRPS I were reviewed separately.
Two investigators independently reviewed all identified trials to determine whether a study should be included. Studies were included if they were double-or single-blinded RCTs with patients suffering from RSD or CRPS I using pain intensity as the main outcome measure. Only studies from the Dutch, German and English literature were included. We excluded non-randomized studies. Case reports and clinical observations were also excluded.
Methodological quality of the studies
Trials concerning treatment effectiveness were scored using a 15-item check list (de Vet et al., 1997) (Table 1) , which included selection and restriction of the study group, treatment allocation, study size, prognostic comparability, dropouts, interventions, extra treatments, blinding procedure, outcome measurements, follow-up period, side-effects and analysis and presentation of data. Each criterion was weighted, resulting in a maximum score of 100 for each study. The essence of a good clinical trial is the (statistical) comparability of the different treatment groups. Thus allocation procedure and drop-out rates are key elements in controlled trials. Therefore, these criteria received the highest possible scores in the check list. Three independent investigators (T. Forouzanfar and W. E. J. Weber reviewed the placebo-controlled studies; T. Forouzanfar and A. J. A. KoÈ ke reviewed active-controlled studies) assessed the methodological quality of the trials. Disagreements were resolved by consensus between the two investigators. If no agreement could be reached a third investigator was consulted. The assessment resulted in a hierarchical list in which higher scores indicate studies with a higher methodological quality. Trials dealing with prevention of RSD or CRPS I were scored using the same methodology.
Outcome of the studies
We considered a study to be positive if the pain intensity was significantly reduced by the therapeutic intervention described when compared with placebo or a control group. A study was classified as`negative' if no difference in pain was achieved by the intervention when compared with the placebo. If the therapeutic intervention under study was more effective, but not significant, the study was classified as`positive not significant'. A similar categorization was used for preventive treatments. These studies were classified positive if RSD/CRPS I was prevented significantly compared with placebo. If no prevention was achieved, then the study was classified as`negative'. If the intervention applied in the study prevented the development of RSD/CRPS I more than placebo, but not significantly so, it was classified as`positive not significant'.
We also investigated the influence of sponsorship of the reviewed studies on the methodological quality of the selected studies.
Statistics
Studies with similar interventions were pooled. A study was regarded as relevant if either pain intensity or prevention of CRPS I was the outcome measure. For methodological quality score we used a cut-off point of 50 as mentioned in the study of van Tulder et al. (1997) . A trial was considered to be of high quality if the methodological score was 50 points or more and of low quality if the score was less than 50 points. The level of evidence for therapeutic intervention effectiveness was graded into four levels based on the quality, outcome and relevance of the studies (van Tulder et al., 1997) . The four levels were strong evidence, moderate evidence, limited evidence and no evidence. Strong evidence was based on multiple relevant, high quality trials; moderate evidence on one relevant, high quality trial and one or more relevant low quality trials.
Limited evidence was classified as one relevant, high quality trial or multiple relevant, low quality trials whereas no evidence was classified as one relevant, low quality trial, no relevant trials or contradictory outcomes.
RESULTS
Methodological flaws
The major methodological flaws in the reviewed studies included poor description of the inclusion and the exclusion criteria, restriction to a homogeneous study population, small study size, lack of details about previous medications and inadequate patients' compliance description (Tables 2±  4) . In most studies it was not clear whether the therapist or the observer was blinded. Moreover, only one study tested whether the blinding procedure was adequate . In 21 studies the treatment was defined as successful when the pain after intervention was significantly reduced compared with baseline Bonelli et al., 1983; Bounameaux et al., 1984; Fialka et al., 1993; Geertzen et al., 1994; Gobelet et al., 1992; Hanna and Peat, 1989; Jadad et al., 1995; Kemler et al., 2000; Kettler and Abram, 1988; Kho, 1995; Korpan et al., 1999; Oerlemans et al., 1999; Rauck et al., 1993; Rocco et al., 1989; Uher et al., 2000; Varenna et al., 2000; Wallace et al., 2000; Wu et al., 1999; Zuurmond et al., 1996) . Only in five studies was a pain reduction of 30% or more compared with baseline defined as a successful Scores of the quality criteria Scores of the quality criteria Scores of the quality criteria treatment Christensen et al., 1982; Hord et al., 1992; Price et al., 1998; Verdugo and Ochoa, 1994) .
Randomized placebo-controlled trials
A total of 18 articles were included in this review. Tables 5 and 6 list these studies according their quality score. Fifteen studies used RSD criteria. From these studies five were published after 1994 Jadad et al., 1995; Kho, 1995; Varenna et al., 2000; Zuurmond et al., 1996) . Three studies used the diagnostic criteria for CRPS I Price et al., 1998; Wu et al., 1999) . The two investigators managed to resolve disagreements by consensus and the third investigator was never involved. Three trials investigated the effectiveness of acupuncture and used sham acupuncture as placebo. These studies were classified as placebo-controlled trials (Hanna and Peat, 1989; Kho, 1995; Korpan et al., 1999) because it was not clear whether sham acupuncture was an active control or a placebo. The quality score of the reviewed papers for RSD ranged from 26.5 to 79. Ten RCTs had a methodological quality score of 50 points or more Blanchard et al., 1990; Gobelet et al., 1986; Jadad et al., 1995; Kettler and Abram, 1988; Rauck et al., 1993; Varenna et al., 2000; Verdugo and Ochoa, 1994; Zuurmond et al., 1996) . These articles were considered to be of high quality. Three studies had a crossover design Jadad et al., 1995; Kettler and Abram, 1988) . The study populations varied between 6 and 66 patients. Treatment modalities included clonidine , calcitonin Gobelet et al., 1986) , clodronate , alendronate , DMSO cream , phentolamine (Verdugo and Ochoa, 1994) , phenylephrine (Verdugo and Ochoa, 1994) , reserpine , guanethidine Jadad et al., 1995) , droperidol (Kettler and Abram, 1988) , prednisolone , acupuncture Kho, 1995) and ketanserin Hanna and Peat, 1989) .
The methodological quality score of the CRPS I studies ranged between 41.5 and 64.5 and the study population between seven and 26 patients Wu et al., 1999; Korpan et al., 1999) . The studies of Price et al. (1998) and Wu et al. (1999) had scores of 64.5 and 59 respectively. These studies were considered to be of high quality. The treatment modalities included sympathetic ganglion blocks , qigong , and acupuncture .
RSD
Sympathetic block. The study performed by Rauck et al. (1993) was classified as high quality. Epidural clonidine 700 mg and 300 mg both decreased pain significantly more than placebo.
The high quality study of Verdugo and Ochoa (1994) demonstrated that neither intravenous phentolamine 35 mg nor phenylephrine 500 mg given to achieve regional sympathetic block were effective for the treatment of RSD.
One study ) tested intravenous reserpine (0.5 mg for the upper extremity; 1 mg for the lower extremity) and intravenous guanethidine (20 mg for the upper extremity; 30 mg for the lower extremity). One further trial on RSD investigated only intravenous guanethidine (10 mg and 30 mg for the upper extremity; 20 mg and 30 mg for the lower extremity). Both articles were of high quality and did not find any improvement compared with placebo.
The high quality study of Kettler and Abram (1988) showed that administration of intravenous droperidol (2.5 mg in 30 ml saline for the upper extremity and 2.5 mg in 50 ml saline for the lower extremity) did not result in any improvement in RSD patients.
Intravenous ketanserin was investigated in two studies Hanna and Peat, 1989) . Bounameaux et al. (1984) administered ketanserin 10 mg in one bolus. There was no significant improvement in pain intensity. Hanna and Peat (1989) Calcium-regulating drugs. Varenna et al. (2000) investigated the efficacy of intravenous clodronate 300 mg given for 10 days. Their trial was of high quality and resulted in a significant improvement in pain reduction in those patients given clodronate compared with the placebo group. Thus there is limited evidence for the efficacy of clodronate. Adami et al. (1997) administered intravenous alendronate 7.5 mg or placebo daily for 3 days. This was a high quality trial with a positive significant result. Two articles Gobelet et al., 1986) were identified using calcitonin (intranasal) as a therapeutic intervention. Both articles were of high quality. In the study with the highest quality score (76), performed by Gobelet et al. (1986) , significant improvement in pain intensity was achieved after intranasal calcitonin 100 IU thrice daily for 3 weeks, whereas in the trial of no improvement was found after administering calcitonin 200 IU intranasally twice daily for 4 weeks.
Radical scavenging. Topical DMSO was tested by Zuurmond et al. (1996) in a high quality study which did not show significant pain reduction.
Corticosteroids. We found one trial that investigated the efficacy of prednisolone 10 mg thrice daily for a maximum period of 12 weeks. Christensen et al. (1982) found a significant improvement after administering prednisolone. However, this trial was of low quality.
Complementary therapies. Two trials (Hanna and Peat, 1989; Kho, 1995) studied the efficacy of acupuncture five times a week for 3 weeks in patients with RSD. They found an improvement compared with sham acupuncture (Hanna and Peat, 1989; Kho, 1995) . However, this improvement was not significant. Both articles were of low quality.
CRPS I
Sympathetic block. Sympathetic ganglion block in CRPS I patients by 1% lidocaine was tested in one high quality study performed by Price et al. (1998) . The results demonstrated that there was a slight improvement after lidocaine, but this improvement was not significant compared with saline.
Complementary therapies. The efficacy of 40 min of qigong exercises twice a week for 4 weeks was investigated by Wu et al. (1999) in a high quality study and significant improvement was noted when compared with sham exercises.
One low quality trial investigated the efficacy of acupuncture five times a week for 3 weeks on CRPS I patients and did not find any improvement .
Randomized active-controlled trials
Eight studies were identified investigating the effectiveness of the treatment modalities by comparing different treatment interventions. The results are shown in Tables 7 and 8 . In six studies RSD diagnostic criteria were used. Two of these studies were published after 1994 . Two studies were identified performing the CRPS I diagnostic criteria Wallace et al., 2000) .
The quality score of the RSD studies ranged between 35 and 65.5. Three studies proved to be of high quality. The interventions consisted of regional intravenous sympathetic blocks Hord et al., 1992; Rocco et al., 1989) , physical therapy , stellate ganglion block and DMSO application .
The methodological quality scores of the studies on CRPS I were 55 and 49.5 Wallace et al., 2000) . The studies investigated the efficacy of lymph drainage and intravenous lidocaine . Hord et al. (1992) administered bretylium 1.5 mg/kg together with 0.5% lidocaine or only 0.5% lidocaine without bretylium. They defined a pain reduction of more than 30% compared with baseline as significant. This high quality study demonstrated that the combination of both treatments resulted in significant pain reduction. compared the effectiveness of guanethidine in a high quality trial. The patients were enrolled to receive four intravenous regional blocks at 4 day intervals with either guanethidine or 0.5% lidocaine. Each patient was randomized to receive one guanethidine and three lidocaine blocks, two guanethidine and two lidocaine blocks or four guanethidine blocks without any lidocaine block. The sympathetic blocks for the upper extremity were done with either 2 ml (20 mg) guanethidine or 0.5% lidocaine 30±50 ml. For the lower extremity the blocks were performed with 4 ml (40 mg) guanethidine or 0.5% lidocaine 40±75 ml. The results did not demonstrate any significant differences between the interventions. In addition, Rocco et al. (1989) , in a low quality randomized crossover study, investigated the effectiveness of guanethidine and reserpine. All patients successively received 20 mg guanethidine in 50 ml 0.5% lidocaine, 1.25 mg reserpine in 50 ml 0.5% lidocaine and 50 ml 0.5% lidocaine with a 1 week interval between medications. No significant reduction in pain was found with either combination therapy.
Stellate ganglion block using 15 ml 0.5% bupivacaine was compared with regional intravenous sympathetic block using guanethidine 20 mg every 4 days to a total of four blocks in a low quality study. This study did not demonstrate any differences between these treatments.
Radical scavenging vs Sympathetic block. Geertzen et al. (1994) compared in a low quality study the effectiveness of dermal application of DMSO 50% four times daily for 3 weeks with regional intravenous sympathetic blockade thrice weekly for 3 weeks. No differences were found between these interventions. CRPS I Sympathetic block. Wallace et al. (2000) administered lidocaine and compared its effectiveness with diphenhydramine. Plasma lidocaine concentration steps of 1 mg/ml, 2 mg/ml and 3 mg/ml were targeted and maintained for 20 min. In this low quality study lidocaine proved to achieve significant improvement.
Complementary therapies. In a study by Uher et al. (2000) the effectiveness of lymph drainage combined with exercise was compared with exercise alone. This high quality study did not show any differences between these interventions.
Prevention of CRPS I
The search for relevant studies concerned with prevention of RSD/CRPS I resulted in two randomized placebo-controlled studies Zollinger et al., 1999) that describe preventive modalities in RSD patients (Tables 4  and 9 ). Both articles were of high quality. In the Zollinger et al. (1999) either placebo or vitamin C 500 mg was administered daily for 50 days in patients with RSD after a Colles' fracture. At 1 year the incidence of RSD in those patients given vitamin C was significantly less than in those in the placebo group. In the other study either saline or intravenous guanethidine 20 mg was administered in patients undergoing faciectomy for Duputyren's disease. They concluded that it is not possible to prevent RSD by giving intravenous guanethidine pre-operatively.
The influence of sponsorship on methodological quality
To investigate the influence of sponsorship on the quality of the selected studies we combined all studies of treatment modalities to one study population. Seven studies of 26 studies were funded Gobelet et al., 1992; Hord et al., 1992; Oerlemans et al., 2000; Rauck et al., 1993; Verdugo and Ochoa, 1994) . The mean methodological quality of the funded studies was significantly higher than the other studies (t-test; p`0.02).
DISCUSSION
We designed the present review to provide a consensus in the treatment or prevention of RSD or CRPS I. RCTs that have examined the effectiveness of treatments and prevention of this disabling disease were reviewed. Generally, the value of a review of the literature depends on the success in obtaining the results of all studies that have been conducted on the subject at issue. Reviews are subject to bias caused by the outcomes of published and unpublished studies differing (publication bias). Although we put much effort into obtaining all the available studies, we may have missed important published and unpublished trials. Furthermore, we were not blinded for the outcomes of the publications in this review, which means that some degree of reviewer bias cannot be excluded. Any reader, however, can check our point assignment and apply different weights to different criteria.
We identified 27 randomized trials, of which 18 were placebo controlled Blanchard et al., 1990; Bounameaux et al., 1984; Christensen et al., 1982; Fialka et al., 1993; Gobelet et al., 1992; Hanna and Peat, 1989; Jadad et al., 1995; Kettler and Abram, 1988; Kho, 1995; Korpan et al., 1999; Price et al., 1998; Rauck et al., 1993; Varenna et al., 2000; Verdugo and Ochoa, 1994; Wu et al., 1999; Zuurmond et al., 1996) . The heterogeneity of the studies and the small sample sizes precluded the drawing of firm conclusions about the efficacy or effectiveness of any of the interventions studied on RSD or CRPS I patients. On basis of our review we conclude that there is limited to no evidence for efficacy of sympathetic blocks (stellate ganglion block or RIS block), radical scavenging, prednisolone administration, acupuncture and manual lymph drainage. Calcium-regulating drugs and qigong exercises seem to be promising treatment modalities. However, further high quality studies are required before the place of these treatments in pain therapy can be established. Further, it is demonstrated that funded studies have better methodological quality than non-funded studies.
The search for eligible trials about prevention resulted in two high quality randomized placebocontrolled studies in which vitamin C and intravenous guanethidine were investigated for RSD patients Zollinger et al., 1999) . Vitamin C prevented RSD while guanethidine did not prevent the development of RSD. Both studies had small sample sizes and no other randomized placebo-controlled studies were identified. Therefore there is limited evidence whether any interventions can significantly prevent RSD.
The major methodological flaws in the reviewed studies included poor description of the inclusion and the exclusion criteria, restriction to a homogeneous study population, small study size, lack of details about previous medications and inadequate patients' compliance description. Mostly, it was not clear whether the therapist or the observer was blinded and only one study
